Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- MHLW Wants to Subject Innovative Add’l Use to PMP, but No Price Raise
November 25, 2019
- MHLW Wants to Ease Unfairness Concerns by Adding New Innovation Gauge to PMP Company Criteria
November 25, 2019
- Industry Urges Careful Approach to Creating Special Rule for Indication Change Re-Pricing: Chuikyo
November 25, 2019
- Japan Approves Add’l Indications for Taltz, Lucentis and More
November 25, 2019
- No Change to Essential Drug Rule in 2020 Reform: MHLW
November 25, 2019
- MHLW Proposes Earlier Price Cuts for Off-Patent Drugs with 80%-Plus Gx Rates, but Chuikyo Questions 2-Year Grace Period
November 25, 2019
- MHLW Proposes Continued Discussions for Cell & Gene Therapy Pricing
November 25, 2019
- PIC/S Reports State of Discussions on Data Integrity Guidance in Japan Meeting: MHLW
November 25, 2019
- US, European Pharma Groups Push LDP to Expedite Vaccine Policies
November 22, 2019
- Upper House Panel Discusses PMD Law Amendment Bill, Another Session Set for Nov. 26
November 22, 2019
- MHLW Proposes 3-Stage Plan to Develop Systems to Promote Genomic Medicine for Intractable Diseases
November 22, 2019
- Chuikyo Discussing Admission Fee for Schizophrenia Patients on Drug Clozapine, Eyeing Transition to Home
November 21, 2019
- MHLW to Propose “Special Rule” for Indication Change Re-Pricing
November 21, 2019
- Japan Grants Orphan Status to Tepotinib and More
November 20, 2019
- 83 ADR Reports from Patients Received in 4 Months after March Launch of New Reporting System: MHLW
November 20, 2019
- Regenerative Medicine Industry Calls for Appropriate Reward for Innovation: Public-Private Confab
November 19, 2019
- MHLW Panel to Discuss Eisai’s Insomnia Med and More on Nov. 29, Skips Ono’s Cachexia Drug Again
November 18, 2019
- Inpatient Generic Use Tops 80% in Japan Hospitals: Chuikyo
November 18, 2019
- 8.2% of Hospitals Have Formularies: Chuikyo Survey
November 18, 2019
- MHLW Orders Label Revisions for Xtandi, Erleada to Include Interstitial Lung Disease to ADR List
November 18, 2019
ページ
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…